Matt Doogue is a consultant physician for Canterbury District Health Board with particular responsibilities in medicines governance and "eMedicines". He co-ordinates Clinical Pharmacology teaching. Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2016). A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology. Lewis, B. C., Nair, P. C., Heran, S. S., Somogyi, A. A., Bowden, J. J., Doogue, M. P., & Miners, J. O. (2016). Warfarin resistance associated with genetic polymorphism of VKORC1: Linking clinical response to molecular mechamism using computational modeling. Pharmacogenetics & Genomics, 26(1), 44-50. Khong, J. J., Burdon, K. P., Lu, Y., Laurie, K., Leonardos, L., Baird, P. N., … Craig, J. E. (2016). Pooled genome wide association detects association upstream of FCRL3 with Graves' disease. BMC Genomics, 17(1), 939.
Chin, P. K. L., & Doogue, M. P. (2016). Long-term prescribing of new oral anticoagulants. Australian Prescriber, 39(6), 200-204. Sanderson, C., Quinn, S. J., Agar, M., Chye, R., Clark, K., Doogue, M., … Pharmacovigilance in hospice/palliative care: Net effect of pregabalinBMJ Supportive & Palliative Care. Authored Book - Other Edited Book - Other Journal - Research Article Beard, M. E. J., Thwaites, J. H., Chambers, S. T., Colls, B. M., Doogue, M., Jeffery,Management guidelines for common medicalChristchurch, NZ: Canterbury District Health Board, 271p. ^ Top of page Begg, E., Barclay, M., Vella-Brincat, J., Gardiner, S. J., Doogue, M., McDermott,Chambers, S., & Murdoch, D. (Eds.). (2004). Preferred Medicines ListChristchurch: The Caxton Press, 172p. Chinnaratha, M. A., Chaudhary, S., Doogue, M., McCormick, R. J., Woodman, R. J., & Wigg, A. J. (2015). Prevalence of hepatic osteodystrophy and vitamin D deficiencyInternal Medicine Journal, 45(12), 1230-1235.
Dobinson, H. C., Anderson, T. P., Chambers, S. T., Doogue, M. P., Seaward, L., & Werno,Antimicrobial treatment options for granulomatous mastitis caused byJournal of Clinical Microbiology, 53(9), Roberts, G. W., Quinn, S. J., Valentine, N., Alhawassi, T., O'Dea, H., Stranks, S.Doogue, M. P. (2015). Relative hyperglycemia, a marker of critical illness: Introducing the Stress Hyperglycemia Ratio. Journal of Clinical Endocrinology & Metabolism, 100(12), 4490-4497. Pharmacovigilance in hospice/palliative care: Net effect of gabapentinBMJ Supportive & Palliative Care, 5, 273-280. Snyder, B. D., Rowland, A., Polasek, T. M., Miners, J. O., & Doogue, M. P. (2014). Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. European Journal of Clinical Pharmacology, 70(9), 1115-1122. Chin, P. K. L., Wright, D. F. B., Patterson, D. M., Doogue, M. P., & Begg, E. J. (2014). A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided
British Journal of Clinical Pharmacology, 78(3), Radhakutty, A., Shen, J., Hooper, A. J., Miller, S. A., Burnett, J. R., Mah, P. M.,Doogue, M. P. (2014). Quantification and genotyping of lipoprotein lipase in patientsDiabetic Medicine, 31(12), 1702-1707. Crawford, G. B., Agar, M. M., Quinn, S. J., Phillips, J., Lister, C., Michael, N.,Currow, D. C. (2013). Pharmacovigilance in hospice/palliative care: Net effect of haloperidol for delirium. Journal of Palliative Medicine, 16(11), Polasek, T. M., Patel, F., Jensen, B. P., Sorich, M. J., Wiese, M. D., & Doogue, M.Predicted metabolic drug clearance with increasing adult age. Journal of Clinical Pharmacology, 75(4), 1019-1028. Kennedy, N. A., Asser, T. L., Mountifield, R. E., Doogue, M. P., Andrews, J. M., & Bampton, P. A. (2013). Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. Internal Medicine Journal, 43(3), To, T. H. M., Agar, M., Shelby-James, T., Abernethy, A. P., Doogue, M., Rowett, D.,
Off-label prescribing in palliative care: A cross-sectional national survey of palliative medicine doctors. Burt, M. G., Mangelsdorf, B. L., Rogers, A., Ho, J. T., Lewis, J. G., Inder, W. J., & Doogue, M. P. (2013). Free and total plasma cortisol measured by immunoassay and mass spectrometry following ACTH1-24 stimulation in the assessment of pituitaryJournal of Clinical Endocrinology & Metabolism, 98(5), Joseph, S. P., Ho, J. T., Doogue, M. P., & Burt, M. G. (2012). of the hypothalamic-pituitary-adrenal axis in patients with pituitary adenomas: AnInternal Medicine Journal, 42(10), 1120-1124. Currow, D. C., Vella-Brincat, J., Fazekas, B., Clark, K., Doogue, M., & Rowett, D. (2012). Pharmacovigilance in hospice/palliative care: Rapid report of net clinicalJournal of Palliative Medicine, 15(10), Doogue, M. P., Begg, E. J., Moore, M. P., Lunt, H., Pemberton, C. J., & Zhang, M. (2009). Metformin increases plasma ghrelin in Type 2 diabetes.
of Clinical Pharmacology, 68(6), 875-882. Schouten, B. J., Doogue, M. P., Soule, S. G., & Hunt, P. J. (2009). FGF23 elevation complicated by hypophosphataemic osteomalacia. Lewis, J. G., möpert, B., Shand, B. I., Doogue, M. P., Soule, S. G., Frampton, C. M., & Elder, P. A. (2006). Plasma variation of corticosteroid-binding globulin andHormone & Metabolic Research, 38, Gardiner, S. J., Doogue, M. P., Zhang, M., & Begg, E. J. (2006). infant exposure to celecoxib through breast milk. British Journal of ClinicalIn November 2012, the Therapeutic Goods Administration announced a new standard for sunscreens sold in Australia, increasing the maximum sun protection factor from SPF30+ to SPF50+. The standard requires the same level of Ultra Violet B (UVB) protection, with improved Ultra Violet A (UVA) protection for new formulas. UVB is the major cause of sunburn and increased skin cancer risk, while UVA contributes to ageing of the skin, as well as skin cancer risk.
The change brings Australia and New Zealand into line with the United States and Europe, where SPF50+ labelling is already allowed. The new standard is likely to see SPF50+ sunscreens on pharmacy and supermarket shelves by mid-January 2013, though some could appear sooner. Cancer Council welcomes the new standards, however the new level of protection should not be overestimated. SPF50+ offers only marginally better protection from Ultra Violet B (UVB) radiation than SPF30+. SPF50+ filters out 98% of UVB radiation compared to 96.7% blocked by SPF30+. SPF50+ sunscreen still needs to be applied just as liberally, re-applied every two hours (or after swimming, exercising and towel drying) and used in combination with other sun protection measures including sun protective hats, protective clothing, sunglasses and shade. New sunscreens carrying an SPF of 30 (not 30+) have also been approved. They will have the same UVB protection as previous SPF30 sunscreens, but are required to have a higher UVA protection in order to be labelled 'broad-spectrum'.
The new standard also means sunscreens can no longer be labelled as 'water proof' or 'sweat proof', as such claims are misleading. They can only be labelled 'water resistant' or 'sweat resistant'. Cancer Council recommends using any sunscreen that is labelled broad spectrum, water-resistant and SPF30 or above. So there is no need to get rid of your current SPF30+ sunscreens, providing they are broad spectrum, water-resistant and have not passed their expiry date. Manufacturers will be allowed to continue producing and selling their current formulations. The new standard applies to new products only. It offers marginally better protection and a little more choice. Whether using SPF30, SPF30+ or SPF50+, application is the key. Apply sunscreen liberally - at least a teaspoon for each limb, front and back of the body, and half a teaspoon for the face, neck and ears. Most people apply less than half this amount, which means they get far less protection than the SPF as stated on the bottle.